<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040738</url>
  </required_header>
  <id_info>
    <org_study_id>7726</org_study_id>
    <nct_id>NCT04040738</nct_id>
  </id_info>
  <brief_title>Plasma Concentration of Somatostatin and Endocannabinoids After GA and RA in Upper Extremity Trauma Surgery</brief_title>
  <acronym>SECsGRUES</acronym>
  <official_title>Comparative Measurement of the Concentration of Blood Somatostatin and Fatty Amid Acids in Upper Extremity Trauma Surgery Under General and Regional Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of RA can decrease the central sensitization and chronic pain after trauma&#xD;
      surgery. The plasma concentrations of somatostatin and fatty acid amides were not studied up&#xD;
      to this time in this kind of settings, so investigators believe that this is the first work&#xD;
      that shows how upper extremity nerve blockade changes the plasma concentration of&#xD;
      somatostatin and fatty acid amides in upper limb surgery in trauma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total of 100 American Society of Anesthesiologist (ASA) I-III, adult patients scheduled to&#xD;
      elective or emergency trauma surgery of hand/forearm or shoulder are planned to be randomly&#xD;
      allocated to general anaesthesia (GA) or ultrasound-guided (UG) brachial plexus block (BPB)&#xD;
      group, in this randomized-prospective study after approval by the University Research Ethics&#xD;
      Board, Pécs University Medical School, Hungary. All of the patients will receive detailed&#xD;
      information about the planned BPB or GA techniques and surgeries, then written informed&#xD;
      consents will be obtained. Study participants are planned to be assigned randomly into 4&#xD;
      groups (Shoulder GA; Shoulder RA; Hand/forearm GA; Hand/forearm RA).&#xD;
&#xD;
      Standardized UG Axillary-supraclavicular (AX-SC) approach to the BP is planned to be&#xD;
      performed under sterile conditions, or standardized GA with propofol IV, fentanyl IV, and 1&#xD;
      MAC (minimal alveolar concentration) sevoflurane, by experienced anesthesiologists.&#xD;
&#xD;
      Blood samples will be taken at 0-time point (straight before the administration of BP&#xD;
      injection or the induction of GA) and straight after the surgery. The collected serum samples&#xD;
      are stored at -70 °C for a maximum of two weeks prior to analysis. Qualitative and&#xD;
      quantitative determination of endocannabinoids and corticosteroids is performed by&#xD;
      supercritical fluid chromatography coupled with tandem mass spectrometry after salting-out&#xD;
      assisted liquid-liquid microextraction. For somatostatin measurement, the samples are&#xD;
      immediately supplemented with aprotinin (20µl/ml blood sample; Gordox 10 KIU/ml (Kallikrein&#xD;
      Inhibitor Unit/ml), Richter Gedeon Budapest, Hungary) and transported for centrifugation on&#xD;
      ice. The pellet is discarded, and the plasma is stored at -80⁰C until further processing. The&#xD;
      somatostatin concentration of the plasma sample is determined with both ELISA (CEA592Hu,&#xD;
      Cloud-Clone Corp., Wuhan, PRC) and radioimmunoassay. The results are collected and analyzed.&#xD;
&#xD;
      Demographic data, vital parameters, and verbal numeric rate of pain intensity are collected&#xD;
      prior to and after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">January 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study participants n=25 in the S-GA, n=25 in the S-RA, n=25 in the H-GA, and n=25 in the H-RA Groups.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The labour analyst, the investigator, the statistician is unaware of group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Somatostatin concentration in plasma</measure>
    <time_frame>0-6 hours after surgery</time_frame>
    <description>Plasma concentrations of somatostatin straight after and 6 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endocannabinoid concentrations in plasma</measure>
    <time_frame>0-6 hours</time_frame>
    <description>Plasma concentrations of endocannabinoids straight after and 6 hours after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid concentrations in plasma</measure>
    <time_frame>0-6 hours</time_frame>
    <description>Plasma concentrations of corticosteroids straight after and 6 hours after surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postoperative pain intensity: verbal numeric rate scale</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Postoperative pain intensity in a 0-10 point verbal numeric rate scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Arm Injury</condition>
  <arm_group>
    <arm_group_label>Upper extremity surgery under general anaesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl 2 mcg/kg iv, propofol 2 mg/kg iv induction, 1MAC sevoflurane maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upper extremity surgery under regional anaesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper extremity surgery under general anaesthesia</intervention_name>
    <description>Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance</description>
    <arm_group_label>Upper extremity surgery under general anaesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper extremity surgery under regional anaesthesia</intervention_name>
    <description>Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14</description>
    <arm_group_label>Upper extremity surgery under regional anaesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  upper extremity fracture&#xD;
&#xD;
          -  surgery of hand/forearm or upper arm&#xD;
&#xD;
          -  unpremedicated patients&#xD;
&#xD;
          -  scheduled for elective or emergency trauma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psycho-mental conditions interfering with consent or assessment&#xD;
&#xD;
          -  the patient refused to participate&#xD;
&#xD;
          -  preexisting chronic pain condition&#xD;
&#xD;
          -  daily analgesic or sedative or steroid consumption&#xD;
&#xD;
          -  sedative or analgesic premedication&#xD;
&#xD;
          -  pre-existing neuro-endocrine disorders&#xD;
&#xD;
          -  antecedent cancer&#xD;
&#xD;
          -  advanced liver or kidney disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Almasi, PhD.Habil.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pecs, Medical School, Clinical Centre, Pain Medicine Dept.of Anesth Int Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zsofia Kriszta, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pecs, Medical School, Clinical Centre, Dept.of Anesth Int Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert G Almasi, PhD.Habil.</last_name>
    <phone>+36304294450</phone>
    <email>almasi.robert@pte.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Pintér, DSC., Prof</last_name>
    <phone>+36204338395</phone>
    <email>erika.pinter@aok.pte.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pécs, Medical School</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Almasi, PhD. habil</last_name>
      <phone>+36304294450</phone>
      <email>robert.almasi@pte.hu</email>
    </contact>
    <contact_backup>
      <last_name>Lajos Bogar, Prof. DSC</last_name>
      <phone>+3672535832</phone>
      <phone_ext>32420</phone_ext>
      <email>bogar.lajos@pte.hu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arm Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

